Are survival rates improved on getfitinib?

Yes, survival rates have been shown to improve with the use of gefitinib, particularly in patients with non-small cell lung cancer (NSCLC) that have specific mutations in the EGFR gene. Clinical trials have demonstrated that gefitinib can lead to better progression-free survival compared to traditional chemotherapy. However, the extent of these benefits can vary based on individual patient factors and the presence of resistance mutations. Overall, gefitinib represents a significant advancement in targeted cancer therapy for eligible patients.